Psilocybin - Pilz Bioscience
Alternative Names: NM-1001; NM-1010; PLZ-1013Latest Information Update: 28 Aug 2024
At a glance
- Originator Pilz Bioscience
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Fragile X syndrome
- No development reported Pervasive child development disorders
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Pervasive-child-development-disorders in Canada
- 08 May 2024 Suspended - Phase-II for Fragile X syndrome (In adults) in Canada (PO) due to indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications (NCT05832255)
- 11 Apr 2023 Nova Mentis Life Science in collaboration with KGK Sciences plans to initiate a phase IIa trial for Fragile X syndrome in Canada